Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439361 · ClinicalTrials.gov registry record · Phase 1
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00439361: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00439361 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00439361, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the toxicity profile of multiple doses of bortezomib when given with ICE in patients with relapsed and refractory classical Hodgkin lymphoma (HL). 2. To determine the maximum tolerated dose (MTD) of bortezomib when given in combination with ICE chemotherapy in patients with relapsed and refractory classical Hodgkin lymphoma (HL). Secondary Objectives: \- To determine the overall response rate and complete response rate in patients with relapsed and refractory classical Hodgkin lymphoma (HL).
Interventions
- DRUG Carboplatin
- DRUG Mesna
- DRUG Etoposide
- DRUG Ifosfamide
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-02 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439361
The ClinicalTrials.gov registry entry for NCT00439361 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00439361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439361 about?
NCT00439361 is a clinical study titled "Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma". Primary Objectives: 1. To determine the toxicity profile of multiple doses of bortezomib when given with ICE in patients with relapsed and refractory classical Hodgkin lymphoma (HL). 2. To determine the maximum tolerated dose (MTD) of bortezomib when given in combination with ICE chemotherapy in pa...
What is the current status of trial NCT00439361?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2007-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00439361?
The interventions under investigation include: Carboplatin (DRUG), Mesna (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00439361?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.